Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amdocs (DOX) Cost of Revenue (2016 - 2024)

Historic Cost of Revenue for Amdocs (DOX) over the last 17 years, with Q3 2025 value amounting to $719.9 million.

  • Amdocs' Cost of Revenue fell 9991.27% to $719.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 9966.02%. This contributed to the annual value of $2.8 billion for FY2025, which is 1348.67% down from last year.
  • Per Amdocs' latest filing, its Cost of Revenue stood at $719.9 million for Q3 2025, which was down 9991.27% from $711.1 million recorded in Q2 2025.
  • In the past 5 years, Amdocs' Cost of Revenue ranged from a high of $824.9 billion in Q3 2024 and a low of $682.3 million during Q4 2024
  • In the last 5 years, Amdocs' Cost of Revenue had a median value of $748.2 million in 2022 and averaged $44.1 billion.
  • As far as peak fluctuations go, Amdocs' Cost of Revenue skyrocketed by 10254907.91% in 2024, and later plummeted by 9991.27% in 2025.
  • Quarter analysis of 5 years shows Amdocs' Cost of Revenue stood at $716.7 million in 2021, then increased by 5.6% to $756.8 million in 2022, then grew by 7.39% to $812.7 million in 2023, then decreased by 16.05% to $682.3 million in 2024, then rose by 5.51% to $719.9 million in 2025.
  • Its last three reported values are $719.9 million in Q3 2025, $711.1 million for Q2 2025, and $698.0 million during Q1 2025.